Compound ID | 516
Class: Rifamycin
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | RNA synthesis inhibitor. RNA polymerase inhibitor |
| Description: | Benzoxazinorifamycin derivative;1. Flamm RK, Karginova E, Rothstein DMDM, et al. In vitro potency and spectrum of novel rifamycins ABI-0043, ABI-0094 and ABI-0299. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;222-223 2. Rothstein DM, Sirokman K, Gwathmey JK, et al. Efficacy of rifalazil and related rifamycins in a mouse model of Helicobacter pylori infection is due to both a luminal and systemic component. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;223 |
| Institute where first reported: | ActivBiotics, Inc., USA |
| Year first mentioned: | 2005 |
| Development status: | Experimental |
| Reason dropped: | Despite having low MICs, it failed to display efficacy unlike ABI-0043 which is now in pre-clinical studies |